Literature DB >> 2177842

In vitro and in vivo analysis of the processing and fate of the peptide products of the short proopiomelanocortin mRNA.

A J Clark1, P M Lavender, P Coates, M R Johnson, L H Rees.   

Abstract

Many peripheral tissues express the proopiomelanocortin (POMC) gene as an 800-base mRNA that lacks the 5' end of the 1200-base pituitary transcript. The missing region encodes the peptide signal sequence, and thus, it is unlikely that any translation product would be secreted. We have found that a RNA transcript equivalent to this short message, generated by transcription in vitro from a T7 polymerase promoter, is translatable in a rabbit reticulocyte lysate, generating peptides of 27.5, 22.5, and 15.5 kD. None of these peptides appears to be processed or protected from proteinase-K digestion by a microsomal membrane fraction. In vivo studies were undertaken by transfecting into GH3 cells one of two expression vectors containing sequences that would produce either a full-length mRNA or a short (800-base) mRNA. The neomycin resistance gene was cotransfected with these plasmids, and 30 permanent cell lines were produced after selection in G418. Cell lines containing the full-length RNA secreted large quantities of ACTH and beta-endorphin immunoreactivity, whereas those expressing the short transcript secreted neither of these peptides. However extractable peptide was present in this latter type of cell line, thereby suggesting that the 800-base mRNA was translated, and that no peptide reached the secretory vesicle. These findings raise important questions about the role of peripheral POMC gene expression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177842     DOI: 10.1210/mend-4-11-1737

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  9 in total

Review 1.  An analysis of vertebrate mRNA sequences: intimations of translational control.

Authors:  M Kozak
Journal:  J Cell Biol       Date:  1991-11       Impact factor: 10.539

2.  An alternative promoter in the mouse major histocompatibility complex class II I-Abeta gene: implications for the origin of CpG islands.

Authors:  D Macleod; R R Ali; A Bird
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

Review 3.  Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research.

Authors:  Markus Böhm; Susanne Grässel
Journal:  Endocr Rev       Date:  2012-06-26       Impact factor: 19.871

Review 4.  Lymphocytes as a source of hormones and peptides.

Authors:  A E Panerai
Journal:  J Endocrinol Invest       Date:  1993 Jul-Aug       Impact factor: 4.256

Review 5.  The human POMC gene promoter: where do we stand?

Authors:  F Pecori Giraldi; F Cassarino; L Pagliardini; V Asnaghi; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

6.  Ectopic adrenocorticotropic hormone syndrome: a diagnostic challenge and review of the literature.

Authors:  Yanjun Ma; Cristi Aitelli; Robin W Dobson; Kartik Konduri
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

Review 7.  60 YEARS OF POMC: Regulation of feeding and energy homeostasis by α-MSH.

Authors:  Erica J P Anderson; Isin Çakir; Sheridan J Carrington; Roger D Cone; Masoud Ghamari-Langroudi; Taneisha Gillyard; Luis E Gimenez; Michael J Litt
Journal:  J Mol Endocrinol       Date:  2016-03-03       Impact factor: 5.098

8.  An Alu element-associated hypermethylation variant of the POMC gene is associated with childhood obesity.

Authors:  Peter Kuehnen; Mona Mischke; Susanna Wiegand; Christine Sers; Bernhard Horsthemke; Susanne Lau; Thomas Keil; Young-Ae Lee; Annette Grueters; Heiko Krude
Journal:  PLoS Genet       Date:  2012-03-15       Impact factor: 5.917

Review 9.  Domestication of farmed fish via the attenuation of stress responses mediated by the hypothalamus-pituitary-inter-renal endocrine axis.

Authors:  Yao Lu; Chuang Shi; Xia Jin; Jiangyan He; Zhan Yin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.